Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry bringing together their collective experiences of drug discovery, drug development, and commercialization. All members of Management Board are also part of Operating Team.
SVP, Chief Human Resources Officer
Karen Anderson joined Alnylam in 2014 from Biogen Idec where she served as Vice President, Human Resources for R&D and Corporate Development. Prior to Biogen Idec, Karen was the Vice President of Human Resources, Commercial for Pfizer Inc. covering both Developed Markets and Emerging Markets. Earlier in her 10-year tenure with Pfizer, Karen supported Worldwide R&D. Before joining Pfizer, she spent 6 years at Baxter, most recently as Global Human Resources Director. Her career as a human resources leader in the bio-pharma industry began in 1995, when she joined Bayer as Director of Compensation from her role as an Associate Consultant with the Hay Group. Karen received a Masters in Organizational Psychology and Development from Bowling Green State University in Ohio. She earned her Bachelor of Arts with honors in both Psychology and Labor Relations from York University in Toronto, Canada and serves on the Board of Directors for Advancing Women in the Enterprise of Science & Technology (WEST).
Chief Commercial Officer
Emmanuel Dulac joined Alnylam in August 2016 and is responsible for establishing Alnylam’s global commercial footprint. He leads the development of the global commercial organization, building global commercial capabilities, including support of patients post product launch, and building the U.S. commercial operations. Emmanuel Dulac brings to Alnylam more than 20 years of international experience in the biotech and pharmaceutical industry. He joins the company from Shire, where he was Senior Vice President, Head of the Rare Disease Business Unit. In this function, Emmanuel led the growth of a portfolio of 5 global brands worth .5bn and developed an innovative patient service hub. Prior to Shire, Emmanuel held various roles of increasing responsibility at Sanofi, Abbott, and Novartis in global, regional and local functions. Emmanuel graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed a Master of Business Administration (MBA) from the ESSEC School in Paris.
Pushkal Garg, M.D.
Chief Medical Officer
Dr. Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development, and oversees our clinical research, clinical operations, biometrics & data management, and medical writing groups. Prior to joining Alnylam, he served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). In this role he was responsible for strategic leadership of the Immunoscience franchise and the successful development of multiple clinical assets across immune-mediated diseases in the areas of rheumatology, gastroenterology, nephrology, and transplantation. During his eight-year tenure at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept) around the world. Previously, Pushkal was at Millennium Pharmaceuticals, where he worked in various roles of increasing responsibility, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders. Pushkal received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining industry.Close Bio
Barry Greene joined Alnylam in 2003, and brings over 25 years of experience in healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE™(bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, his past experiences include Vice President of Marketing and Customer Services for AstraZeneca, formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Barry received his B.S. in Industrial Engineering from University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Boards of Acorda Therapeutics and Karyopharm Therapeutics.
Chief Operating Officer
Yvonne brings 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management. She has successfully led product development and commercialization teams in a wide range of therapy areas, bringing new medicines to patients. Yvonne was previously Senior Vice President and Head of Medicines Development at Pfizer, and a member of the executive team for the speciality business, with accountability for a portfolio that included the immuno-inflammation, vaccine, speciality neuroscience, and rare disease areas. Prior to Pfizer, she held roles of increasing responsibility at Glaxo SmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development and Chief Medical Officer for Europe. Yvonne holds a Bachelor of Medicine, Bachelor of Surgery from the University of Leeds, UK and Master of Business Administration (MBA) from INSEAD, France.
SVP, General Counsel, and Secretary
John Maraganore, Ph.D.
Chief Executive Officer
Since 2002, John Maraganore has served as the CEO and a Director of Alnylam. Prior to Alnylam he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inﬂammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and prior to that he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of Angiomax™ (bivalirudin for injection, formerly Hirulog™) currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. Dr. Maraganore is a Director for bluebird bio and is the Chairman of the Board for Agios Pharmaceuticals. Dr. Maraganore is a member of the Biotechnology Industry Organization (BIO) Board and the BIO Executive Committee, and serves as the chair of the Emerging Company Section and as co-chair of the Regulatory Environment Committee.
Akshay Vaishnaw, M.D., Ph.D.
Executive VP of R&D
Dr. Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Akshay received his M.D. from the University of Wales College of Medicine, U.K., and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Scientific Advisory Board of Scholar Rock, and a member of the Board of Directors for Visterra, Inc. and for Editas Medicine. In addition, he has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.